Bavarian Nordic: Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
125 Patient, Prospective Randomized Placebo-Controlled Phase II Study
09-Oct-2008 -
Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.
The results from the Phase II prospective ...
advanced androgen-dependent carcinoma of the prostate
medicine
phase III studies
+1